Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Ascierto, Paolo Antonio; Del Vecchio, Michele; Mackiewicz, Andrzej; Robert, Caroline; Chiarion-Sileni, Vanna; Arance, Ana; Lebbe, Celeste; Svane, Inge Marie; McNeil, Catriona; Rutkowski, Piotr; Loquai, Carmen; Mortier, Laurent; Hamid, Omid; Bastholt, Lars; Dreno, Brigitte; Schadendorf, Dirk; Garbe, Claus; Nyakas, Marta; Grob, Jean-Jacques; Thomas, Luc; Liszkay, Gabriella; Smylie, Michael; Hoeller, Christoph; Ferraresi, Virginia; Grange, Florent; Gutzmer, Ralf; Pikiel, Joanna; Hosein, Fareeda; Simsek, Burcin; Maio, Michele

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Autor(en):

Ascierto, Paolo Antonio; Del Vecchio, Michele; Mackiewicz, Andrzej; Robert, Caroline; Chiarion-Sileni, Vanna; Arance, Ana; Lebbe, Celeste; Svane, Inge Marie; McNeil, Catriona; Rutkowski, Piotr; Loquai, Carmen; Mortier, Laurent; Hamid, Omid; Bastholt, Lars; Dreno, Brigitte; Schadendorf, Dirk; Garbe, Claus; Nyakas, Marta; Grob, Jean-Jacques; Thomas, Luc; Liszkay, Gabriella; Smylie, Michael; Hoeller, Christoph; Ferraresi, Virginia; Grange, Florent; Gutzmer, Ralf; Pikiel, Joanna; Hosein, Fareeda; Simsek, Burcin; Maio, Michele

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

Journal For Immunotherapy of Cancer (2020), Bd. 8, Article E000391

Verlagsangabe:

Bmj Publishing Group

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1136/jitc-2019-000391

ISSN:

2051-1426